Codiak BioSciences Logo
US1920101060
A2PJN7
CDAK

Codiak BioSciences

Forecast

Buy
  1
Hold
  1
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last year, Codiak BioSciences had revenue of €20.17M and net profit of -€36.61M

(EUR) 2021
YoY
Revenue 20.17M 742.65%
Gross profit 20.17M 742.65%
Net profit -36.61M 49.86%
EBITDA -24.66M 64.34%

Fundamentals

Metric Value
Market capitalization
€0
52-week high/low
€3.87 - €0.0155
Dividends No
Beta
3.93
P/E ratio
-0.03
PEG ratio
0.00
P/B ratio
0.02
P/S ratio
0.00

Company profile

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Name
Codiak BioSciences
CEO
Douglas Edward Williams
Headquarters Cambridge, ma
USA
Website
Sector
Consumer Staples
Industry
Food Products
IPO
10/14/2020
Employees 102

Ticker symbols

Exchange Symbol
NASDAQ
CDAK
SIX
32W.SW
🍪

Parqet  uses cookies. Learn more